Rigel Says First Patient Enrolled In Phase 1b/2 Triplet Therapy Trial Of Decitabine And Venetoclax In Combination With REZLIDHIA
Portfolio Pulse from Benzinga Newsdesk
Rigel Pharmaceuticals has announced the enrollment of the first patient in a Phase 1b/2 trial for a triplet therapy involving Decitabine, Venetoclax, and REZLIDHIA. This trial marks a significant step in the development of new treatment options.
September 05, 2024 | 11:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Rigel Pharmaceuticals has initiated a Phase 1b/2 trial for a new triplet therapy, enrolling the first patient. This development could potentially enhance the company's treatment portfolio.
The initiation of a clinical trial and the enrollment of the first patient is a positive development for Rigel Pharmaceuticals, indicating progress in their drug development pipeline. This could lead to future revenue streams if the trial is successful, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100